Charles Schwab Investment Management Inc. Buys 167,997 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

Charles Schwab Investment Management Inc. increased its stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 9.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,931,114 shares of the company's stock after purchasing an additional 167,997 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.15% of Revolution Medicines worth $84,467,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Janus Henderson Group PLC raised its holdings in Revolution Medicines by 32.3% in the 3rd quarter. Janus Henderson Group PLC now owns 6,137,244 shares of the company's stock worth $278,280,000 after purchasing an additional 1,497,026 shares during the period. FMR LLC raised its holdings in Revolution Medicines by 4.4% in the 3rd quarter. FMR LLC now owns 5,875,893 shares of the company's stock worth $266,472,000 after purchasing an additional 250,037 shares during the period. State Street Corp raised its holdings in Revolution Medicines by 4.1% in the 3rd quarter. State Street Corp now owns 5,279,584 shares of the company's stock worth $239,429,000 after purchasing an additional 208,516 shares during the period. Geode Capital Management LLC raised its holdings in Revolution Medicines by 8.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,627,025 shares of the company's stock worth $164,517,000 after purchasing an additional 291,369 shares during the period. Finally, Lord Abbett & CO. LLC bought a new position in Revolution Medicines in the 3rd quarter worth $83,082,000. 94.34% of the stock is owned by institutional investors.

Remove Ads

Revolution Medicines Stock Down 0.4 %

RVMD traded down $0.17 on Thursday, hitting $39.03. The company had a trading volume of 845,376 shares, compared to its average volume of 1,363,443. The company has a market cap of $7.26 billion, a PE ratio of -10.87 and a beta of 1.46. Revolution Medicines, Inc. has a 12-month low of $29.55 and a 12-month high of $62.40. The business's fifty day simple moving average is $41.18 and its 200 day simple moving average is $45.88.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.11). On average, analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 2,635 shares of the business's stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $45.40, for a total transaction of $119,629.00. Following the completion of the transaction, the chief financial officer now owns 96,470 shares in the company, valued at $4,379,738. The trade was a 2.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mark A. Goldsmith sold 11,714 shares of the business's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $45.40, for a total value of $531,815.60. Following the transaction, the insider now owns 325,056 shares of the company's stock, valued at $14,757,542.40. This trade represents a 3.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,678 shares of company stock worth $847,981 over the last 90 days. Company insiders own 8.00% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have commented on RVMD shares. UBS Group raised their price target on Revolution Medicines from $65.00 to $71.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. Needham & Company LLC decreased their price target on Revolution Medicines from $60.00 to $59.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. JPMorgan Chase & Co. raised their price target on Revolution Medicines from $63.00 to $71.00 and gave the company an "overweight" rating in a report on Tuesday, December 3rd. Guggenheim raised their price target on Revolution Medicines from $82.00 to $87.00 and gave the company a "buy" rating in a report on Tuesday, December 3rd. Finally, Wedbush reissued an "outperform" rating and set a $67.00 price target on shares of Revolution Medicines in a report on Thursday, February 27th. Twelve analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Revolution Medicines presently has an average rating of "Buy" and an average target price of $66.31.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.